{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-031632","form_type":"8-K","ticker":"XFOR","cik":"0001501697","company_name":"X4 Pharmaceuticals, Inc","filed_at":"2022-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.885226+00:00","generated_at":"2026-06-21T06:45:36.639385+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"X4 Pharmaceuticals prices $65M public offering of common stock and warrants","bullets":["Offering includes 52.3M shares and 6.8M pre-funded warrants at $1.10/share.","Class C warrants to purchase 29.55M shares at $1.50/share, expiring Dec 2027.","Gross proceeds $65M; net proceeds ~$59.8M after discounts and expenses.","Underwriters granted 30-day option for up to 8.865M additional shares.","Closing expected Dec 9, 2022; Piper Sandler, Stifel, Cantor as joint bookrunners."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-031632","json":"https://secwatch.observer/filing/0001628280-22-031632.json","markdown":"https://secwatch.observer/filing/0001628280-22-031632.md","text":"https://secwatch.observer/filing/0001628280-22-031632.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501697/000162828022031632/0001628280-22-031632-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501697/000162828022031632/xfor-20221206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T06:45:36.639385+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d2d381b2f58db2f0e372cde17c8dbe031889c099","claim":"X4 Pharmaceuticals, Inc entered into Underwriting Agreement with Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated and Cantor Fitzgerald & Co., as representatives of the several underwriters valued at approximately $59.8 million (effective 2022-12-07).","evidence_excerpt":"On December 7, 2022, X4 Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale (the “Offering”) of 52,300,000 shares of the Company’s common stock, pre-funded warrants to purchase 6,800,000 shares of the Company’s common stock (the “Pre-Funded Warrants”) and Class C warrants to purchase 29,550,000 shares of the Company’s common stock or Pre-Funded Warrants (the “Class C Warrants”) at a price to the public of $1.10 per share for common stock and accompanying Class C Warrant and $1.099 per Pre-Funded Warrant and accompanying Class C Warrant.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828022031632/0001628280-22-031632-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated and Cantor Fitzgerald & Co., as representatives of the several underwriters"},{"label":"Value","value":"approximately $59.8 million"},{"label":"Effective","value":"2022-12-07"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}